CRIZANLIZUMAB

UNII:	L7451S9126
Formula:
Preferred Substance Name:	CRIZANLIZUMAB

1690318-25-2
ADAKVEO
CRIZANLIZUMAB [INN]
CRIZANLIZUMAB [MI]
CRIZANLIZUMAB [USAN]
CRIZANLIZUMAB [WHO-DD]
CRIZANLIZUMAB TMCA [WHO-DD]
CRIZANLIZUMAB-TMCA
IMMUNOGLOBULIN G2, ANTI-(HUMAN P-SELECTIN) (HUMAN-MUS MUSCULUS MONOCLONAL SELG1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SELG1 LIGHT CHAIN, DIMER
IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS P-SELECTIN GLYCOPROTEIN LIGAND (CD62 ANTIGEN))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.2 HEAVY CHAIN (1-448) (HUMANIZED VH (HOMO SAPIENS IGHV1-8*01 (82%) (IGHD)-IGHJ4*01) (8.8.15) (1-122) -HOMO SAPIENS IGHG2*02 (CH2(K105>A(323))) (123-448)) (136-218')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-218') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (87%) IGKJ4*01) (10.3.9) (1'-111') -HOMO SAPIENS IGKC*01 (112'-218')), DIMER (224-224'':225-225'':228-228'':231-231'')-TETRAKISDISULFIDE
NVP-LXI262
NVP-LXI-262
SEG101
SEG-101
SELG1
SEL-G1

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CRIZANLIZUMAB

Synonyms and Mappings

Resources